Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Pipeline Promise | Explore Kodiaq Sciences' diverse eye disease treatment portfolio, including KSI-101, tarcocimab, and KSI-501, with key trial results expected in 2025-2026 |
Financial Hurdles | Delve into the company's financial challenges, with negative EPS forecasts and a declining stock price, balanced against its cash-rich balance sheet |
Market Positioning | Learn how Kodiaq Sciences aims to differentiate itself in the competitive biotech sector through innovative treatments and a new wearable OCT device |
Future Outlook | Analyst price targets range from $3 to $4, reflecting cautious optimism amid clinical trial uncertainties and potential market opportunities |
Metrics to compare | KOD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKODPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.4x | −1.9x | −0.5x | |
PEG Ratio | −0.13 | −0.04 | 0.00 | |
Price/Book | 4.3x | 0.9x | 2.6x | |
Price / LTM Sales | - | 81.9x | 3.2x | |
Upside (Analyst Target) | −58.3% | 264.5% | 41.7% | |
Fair Value Upside | Unlock | 14.9% | 6.1% | Unlock |